Report
Cosmo Pharmaceuticals NV
Riverside II, Sir John Rogerson's Quay
Phone: +353 18170370p:+353 18170370 DUBLIN, Ireland Ticker: COPNCOPN


Acacia Pharma Announces Early Repayment of Loan Facility from Hercules Technology Growth Capital and Reduction in Debt Service Obligations


THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

Acacia Pharma Announces Early Repayment of Loan Facilityfrom Hercules Technology Growth Capital

Reduction in Debt Service Obligations

Cambridge, UK and Indianapolis, US – 4May 2021, 07:00 CEST:Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces the early repayment and settlement in full of its debt facility with Hercules Technology Growth Capital, Inc. (“Hercules”) (NYSE: HTGC) and, pursuant to the debt facility agreement already in place with Cosmo Pharmaceuticals N.V. (“Cosmo”), the proposed granting of security to Cosmo in consideration for a reduction in the coupon rate.

Acacia Pharma has made early repayment in full settlement of all amounts outstanding under its loan facility from Hercules, as provided for under the terms of the Hercules loan facilty agreement (the “Hercules Agreement”), announced on 2 July 2018. This early repayment, totalling approximately $4.3 million, satisfies in full the Company’s obligations under the Hercules Agreement and as a result, all security provided by Acacia Pharma to Hercules under the Hercules Agreement will be released.

Under the terms of the debt facility currently in place with Cosmo, the Company is to grant security to Cosmo on materially similar terms to those granted under the Hercules Agreement in consideration for a reduction in the coupon payable on the Cosmo debt facility of 200 basis points (9% versus 11%). This will lead to a reduction in the amount of interest payable by Acacia Pharma of approximately €500k per annum.

The terms on which security will be granted to Cosmo will be finalised as soon as reasonably practicable following this announcement.

Gary Gemignani, Acacia Pharma CFO, commented: “The actions that we are taking will lower our annual debt service costs and allow us to deploy more of our capital to fund the launch of our products. We will continue to look for ways to further finance the growth of our business under favorable commercial terms, as we progress the successful commercialization of BARHEMSYS® and BYFAVO™ in the US.“

Contacts

Acacia Pharma Group plc
Mike Bolinder, CEO
Gary Gemignani, CFO
+44 1223 919760 / +1 317 505 1280
IR@acaciapharma.com

International Media
Mark Swallow, Frazer Hall, David Dible
Citigate Dewe Rogerson
+44 20 7638 9571
acaciapharma@citigatedewerogerson.com
US Investors
LifeSci Advisors
Irina Koffler
+1 917-734-7387
ikoffler@lifesciadvisors.com
Media in Belgium and the Netherlands
Chris Van Raemdonck
+32 499 58 55 31
chrisvanraemdonck@telenet.be

About Acacia Pharma

Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy. The Company has identified important and commercially attractive unmet needs in these areas that its product portfolio aims to address.

Acacia Pharma's first product, BARHEMSYS® (amisulpride injection) is available in the US for the management of postoperative nausea & vomiting (PONV).

BYFAVO™ (remimazolam) for injection, a very rapid onset/offset IV benzodiazepine sedative is approved and launched in the US for use during invasive medical procedures in adults lasting 30 minutes or less, such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion UK Limited for the US market.

APD403 (intravenous and oral amisulpride), a selective dopamine antagonist for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.

Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D operations are centred in Cambridge, UK. The Company is listed on the Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker symbol ACPH.

Acacia Pharma Group plc
The Officers’ Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United Kingdom
Company number 9759376

www.acaciapharma.com



Related Businesses
- - Customer

Copyright © 2021 by CreditRiskMonitor.com (Ticker: CRMZ®). All rights reserved.  You are not permitted to use this report or the information contained herein for any purpose not expressly permitted by CreditRiskMonitor.com, Inc. Except as expressly permitted by CreditRiskMonitor.com, Inc., you are not permitted, in whole or in part, to copy, alter, correct, adapt, translate, enhance, lease, sell, sublicense, assign, distribute, publish, otherwise make available to any third party, or prepare derivative works or improvements of this report or any of the information contained therein. You are not permitted to reverse engineer, disassemble, decompile, decode, or adapt the software, algorithms or other processes used to prepare this report, or otherwise attempt to derive or gain access to the source code of same. You agree not to remove, alter, obscure, combine or otherwise change any disclaimers, trademarks, copyrights, other intellectual property rights, proprietary rights, or other symbols, notices, marks, or serial numbers on or relating to any copy of the report or on marketing or other materials that CreditRiskMonitor.com, Inc. may provide to you. You will not use this report in any manner or for any purpose that infringes, misappropriates, or otherwise violates any right of any party, or that violates any applicable law.  
The FRISK® scores, agency ratings, credit limit recommendations and other scores, analysis and commentary are opinions of CreditRiskMonitor.com, Inc. and/or its suppliers, not statements of fact, and should be one of several factors in making credit decisions.  Any reliance you place on the information in this report is strictly at your own risk. Except as expressly provided by CreditRiskMonitor.com, Inc., no warranties or representations of any type, including without limitation of results to be obtained, merchantability or fitness for a particular purpose, are made concerning any part of CreditRiskMonitor.com, Inc.’s service, including without limitation the FRISK® scores.  The information published above has been obtained from sources CreditRiskMonitor considers to be reliable.  CreditRiskMonitor.com, Inc. and its third-party suppliers do not guarantee or validate the accuracy and completeness of the information provided in this report, the underlying information input to create the FRISK® scores, and specifically do not assume responsibility for not reporting any information omitted or withheld.  By using this website, you accept the Terms of Use Agreement
Contact Us: 845.230.3000
Fundamental financial data concerning public companies may be provided by Refinitiv (click for restrictions)
Tuesday, May 11, 2021